Brief: Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC
05/04/2024 13:08
April 5 (Reuters) - Protara Therapeutics Inc TARA.O :
* PROTARA THERAPEUTICS ANNOUNCES POSITIVE THREE-MONTH DATA
FROM
TARA-002 CLINICAL PROGRAM IN NMIBC
* PROTARA THERAPEUTICS INC - PRELIMINARY DATA FROM SIX-MONTH
EVALUABLE PATIENTS IN ADVANCED-2 TRIAL OF TARA-002 IN NMIBC
EXPECTED IN 2H 2024
* PROTARA THERAPEUTICS - TARA-002 DEMONSTRATED A FAVORABLE
SAFETY
AND TOLERABILITY PROFILE WITH NO GRADE 3 OR GREATER
TREATMENT-RELATED ADVERSE EVENTS
Source text for Eikon: ID:nGNX48MRsD
Further company coverage: TARA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses